• WELL Health and AliveCor have partnered to bring rapid, cardiologist-reviewed ECG services to patients across Canada through the Kardia platform.
• Under this partnership, WELL Health’s Canadian-registered cardiologists are integrated directly into AliveCor’s AI-powered Kardia platform, providing paid clinical interpretation services that give patients expert, physician-validated insight into their heart data, all from home.
• Cardiologist-reviewed ECG results are shared directly with the patient in under 24 hours, helping patients avoid delays for in-person care.

VANCOUVER, British Columbia -- (Business Wire)

WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce a strategic partnership with AliveCor, Inc. (“AliveCor”), the global leader in AI-powered personal electrocardiogram (ECG) technology, in which Canadian-registered cardiologists from WELL’s network will provide ECG reviews to Canadian consumers who are users of AliveCor’s ECG technology, offering a “second set of eyes” on their heart health metrics. The collaboration integrates WELL Health’s expanding national network of Canadian-licensed cardiologists with AliveCor’s Kardia solution and services, enabling patients to receive timely, expert clinical interpretation of their heart data from home.

Through the Kardia app, Canadian users can now request a Clinician Review after recording an ECG using a Kardia device. Once submitted, the ECG is evaluated within 24 hours by a Canadian-registered cardiologist from WELL Health’s network. Each review provides a more comprehensive clinical evaluation to confirm or refine the initial AI result from Kardia, along with clear written physician guidance on potential next steps for care.

At the foundation of AliveCor’s technology is clinical AI that is cleared to detect life-threatening cardiac conditions. AliveCor’s Kardia app is powered by Health Canada-licensed AI algorithms capable of instantly detecting three of the most common heart arrhythmias in a 30-second recording. With more than 350 million ECGs recorded to date, Kardia is one of the most clinically validated personal ECG solutions in the world. The Clinician Review service adds a critical human layer to this AI-driven analysis: after Kardia’s AI delivers its initial determination, a Canadian-registered cardiologist from WELL Health’s network provides a comprehensive clinical evaluation, confirming or refining the AI result and offering written physician guidance on next steps. WELL Health is compensated for each cardiologist review performed, generating clinical services revenue while expanding the reach of its specialist physician network into the growing remote cardiac monitoring market.

The service is designed to bridge the gap between personal heart monitoring and specialist care, delivering faster insights at a time when access to cardiology services remains constrained across Canada. Elective cardiology wait times have increased by 53%⁽¹⁾ over the last year, with patients waiting an average of 15.3 weeks for specialist consultation⁽²⁾. By enabling rapid access to cardiologist expertise, this service aims to support earlier clinical decision-making, reduce unnecessary emergency visits, and provide patients with greater confidence in managing their heart health.

Dina Sergi, CEO of WELL Health Diagnostic Centres, commented, “This partnership pairs the clinical expertise of WELL’s cardiologist network with some of the most advanced AI-powered cardiac monitoring technology in the world. By providing clinician review to AliveCor’s AI-driven analysis, we are helping patients get answers faster, reducing pressure on the healthcare system, and creating a new, scalable clinical services revenue stream for WELL.”

Navneet Malpani, Senior Vice President of Partner Alliances at AliveCor, commented, “AliveCor is committed to delivering the most clinically validated heart care tools to patients worldwide. By partnering with WELL Health, Canada’s leader in modern outpatient care, we are providing our Canadian customers with an essential layer of clinical oversight. Patients can receive expert guidance from a certified cardiologist when they need it most, without having to wait for in-person appointments.”

As part of the partnership, WELL Health will consider opportunities to support the broader adoption of AliveCor's Kardia remote cardiac monitoring solutions throughout WELL's national network. This launch represents the first phase of the partnership, with opportunities to expand access to additional services and markets over time. Future phases may include deploying AliveCor’s Kardia 12L, a pocket-sized, AI-powered 12-lead ECG system designed for use in primary care, urgent care, and outpatient settings, directly within WELL’s clinic network, further expanding point-of-care cardiac diagnostic capabilities across Canada.

Footnotes:

1. BBD, ‘2025 Canada’s Health Care Wait Times’ published on January 30, 2025.
2. Fraser Institute, Waiting Your Turn: Wait Times for Health Care in Canada, 2025 Report, published on December 9, 2025.

WELL HEALTH TECHNOLOGIES CORP.
Per: “Hamed Shahbazi”
Hamed Shahbazi
Chief Executive Officer, Chairman and Director

About WELL Health Technologies Corp.

WELL is building the infrastructure for a healthier Canada. Through its comprehensive healthcare and digital platforms, WELL operates the largest owned and operated outpatient healthcare ecosystem in Canada with more than 250 clinics, and its technology solutions enable more than 43,000 healthcare providers across Canada and the US. WELL's subsidiaries include WELLSTAR, a pure-play healthcare SaaS platform, HEALWELL AI, a global healthcare AI company, and CyberWELL, a healthcare cybersecurity division. WELL is publicly-traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about WELL, please visit: www.well.company.

About AliveCor, Inc.

AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the inaugural TIME World's Top Health Tech Companies 2025 list - recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 350 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L cleared to detect 39 cardiac conditions (with determination availability varying by geography), was designed exclusively for use by healthcare providers. AliveCor's enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook.

Forward Looking Statements

This news release contains “Forward-Looking Information” within the meaning of applicable Canadian securities laws, including, the promotion of the Kardia solution across the WELL network and future expansion plans. Forward-Looking Information is based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies outside of WELL’s control. Such Forward-Looking Information are not guarantees of future performance or that WELL will be the beneficiary of such statement. WELL’s comments expressed or implied by such Forward-Looking Information are subject to a number of risks, uncertainties, and conditions, many of which are outside of WELL‘s control, and undue reliance should not be placed on such information. Forward-Looking Information are qualified in their entirety by inherent risks and uncertainties, including: direct and indirect material adverse effects from adverse market conditions; risks inherent in the primary healthcare and technology sector in general; regulatory and legislative changes; that market competition may affect the business, results and financial condition of WELL and other risk factors identified in documents filed by WELL under its profile at www.sedarplus.com, including its most recent Annual Information Form and its Management, Discussion and Analysis. Except as required by securities law, WELL does not assume any obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260402439005/en/

Contacts:

For further information:

Pardeep Sangha
Vice President, Investor Relations
investor@well.company
604-628-7266

Morgan Mathis
Director, Corporate Communications
mmathis863@alivecor.com

Source: WELL Health Technologies Corp.